FIELD: chemistry.
SUBSTANCE: present invention refers to immunology. There are presented versions of a human thymic stromal lymphopoietin (hTSLP) receptor antibodies characterised by the presence of variable reionso of a heavy and light chain or 3 CDR of a light chain and 3 CDR of a heavy chain respectively. There are described versions of a recovered or recombinant coding polynucleotide, a recovered host cell for producing the antibody containing coding DNAs. There is also described a method of treating an hTSLP-mediated inflammatory disorder involving the administration of a pharmaceutical composition containing an effective amount of the antibody.
EFFECT: using the invention provides the new hTSLP antibodies that can find application in medicine for treating the inflammatory diseases associated with hTSLP activity.
27 cl, 08 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY TO TSLP-RECEPTOR OF HUMAN | 2014 |
|
RU2689528C2 |
| MOLECULES BINDING TO THYMIC STROMAL LYMPHOPOIETIN (TSLP), AND METHODS OF USING SUCH MOLECULES | 2016 |
|
RU2731644C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTIBODIES SPECIFIC TO HUMAN CD22, AND THEIR USES IN THERAPY AND DIAGNOSTICS | 2003 |
|
RU2342401C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| CONSTRUCTED ANTI-TSLP ANTIBODY | 2010 |
|
RU2575039C2 |
| ANTIBODIES RECOGNISING EPITOPE ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS AND METHODS FOR USING THEM | 2008 |
|
RU2528738C2 |
| ANTIBODIES AND POLYPEPTIDES AGAINST CD127 | 2017 |
|
RU2769352C2 |
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
